PCSK9 and hyperlipidemia: For example, using the SNPs reported in seven studies as genetic instrumental variables, the risk of hyperlipidemia was augmented by increased APOB (OR = 3.28; 95% CI, 1.78–6.04; P = 1.44e-04), NCAN (OR = 1.41; 95% CI, 1.16–1.71; P = 4.73e-04), and PCSK9 (OR = 1.39; 95% CI, 1.25–1.54; P = 1.00e-09).